

C Blake Gilks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1384286/publications.pdf>

Version: 2024-02-01

371
papers

35,183
citations

2203

99
h-index

4628

170
g-index

376
all docs

376
docs citations

376
times ranked

29210
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5367-5374.	3.2	2,393
2	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. <i>New England Journal of Medicine</i> , 2010, 363, 1532-1543.	13.9	1,460
3	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. <i>Nature</i> , 2011, 475, 226-230.	13.7	1,071
4	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , The, 2011, 12, 852-861.	5.1	1,028
5	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. <i>New England Journal of Medicine</i> , 2009, 360, 2719-2729.	13.9	706
6	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. <i>PLoS Medicine</i> , 2008, 5, e232.	3.9	675
7	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , 2017, 123, 802-813.	2.0	552
8	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 690-695.	3.3	474
9	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
10	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. <i>New England Journal of Medicine</i> , 2012, 366, 234-242.	13.9	401
11	EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer. <i>Cell</i> , 2003, 115, 523-535.	13.5	389
12	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412.	1.1	354
13	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	5.1	335
14	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 203-211.	0.9	332
15	Mucinous Tumors of the Appendix Associated With Mucinous Tumors of the Ovary and Pseudomyxoma Peritonei. <i>American Journal of Surgical Pathology</i> , 1991, 15, 415-429.	2.1	325
16	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. <i>Genome Research</i> , 2014, 24, 1881-1893.	2.4	322
17	Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 874-881.	2.1	309
18	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , 2016, 48, 758-767.	9.4	287

#	ARTICLE	IF	CITATIONS
19	Adenoma Malignum (Minimal Deviation Adenocarcinoma) of the Uterine Cervix. American Journal of Surgical Pathology, 1989, 13, 717-729.	2.1	270
20	The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2012, 36, 641-653.	2.1	265
21	Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology, 2012, 228, 20-30.	2.1	261
22	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	13.5	261
23	Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. Journal of Clinical Oncology, 2008, 26, 5697-5704.	0.8	260
24	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
25	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	2.9	241
26	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	3.3	239
27	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. American Journal of Obstetrics and Gynecology, 2014, 210, 471.e1-471.e11.	0.7	236
28	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nature Reviews Cancer, 2017, 17, 65-74.	12.8	235
29	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology, 2008, 39, 1239-1251.	1.1	231
30	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. International Journal of Gynecological Pathology, 2019, 38, S123-S131.	0.9	226
31	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	9.4	220
32	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Modern Pathology, 2014, 27, 128-134.	2.9	218
33	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	3.2	217
34	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. American Journal of Surgical Pathology, 2018, 42, 561-568.	2.1	214
35	Ovarian carcinoma pathology and genetics: recent advances. Human Pathology, 2009, 40, 1213-1223.	1.1	211
36	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	2.1	211

#	ARTICLE	IF	CITATIONS
37	Loss of BAF250a (<i>ARID1A</i>) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , 2011, 224, 328-333.	2.1	210
38	Clinicopathological and molecular characterisation of a "multiple-classifier"™ endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	2.1	205
39	Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2457-2463.	0.8	203
40	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	2.1	203
41	Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6143-6151.	3.2	198
42	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. <i>American Journal of Pathology</i> , 2002, 161, 1557-1565.	1.9	194
43	Cyclin D1 as a Diagnostic Immunomarker for Endometrial Stromal Sarcoma With YWHAE-FAM22 Rearrangement. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1562-1570.	2.1	184
44	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 484-494.	2.1	183
45	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 430-441.	0.9	180
46	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. <i>Breast Cancer Research and Treatment</i> , 2008, 107, 249-257.	1.1	179
47	Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. <i>Journal of Clinical Oncology</i> , 2006, 24, 5637-5644.	0.8	177
48	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018, 119, 1401-1409.	2.9	175
49	Dual loss of the <i>SWI/SNF</i> complex <i>ATPases SMARCA4</i> and <i>BRG1</i> and <i>SMARCA2</i> / <i>BRM</i> is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016, 238, 389-400.	2.1	169
50	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015, 28, 1101-1122.	2.9	164
51	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. <i>International Journal of Gynecological Pathology</i> , 2019, 38, S40-S63.	0.9	164
52	p53 immunohistochemistry is an accurate surrogate for <i>TP53</i> mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020, 250, 336-345.	2.1	164
53	Endocervical Adenocarcinomas With Ovarian Metastases. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1835-1853.	2.1	157
54	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016, 143, 46-53.	0.6	153

#	ARTICLE	IF	CITATIONS
55	Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas. <i>Clinical Cancer Research</i> , 2008, 14, 1423-1430.	3.2	152
56	Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum. <i>American Journal of Clinical Pathology</i> , 2010, 134, 835-845.	0.4	152
57	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	2.9	151
58	Assessment of Interlaboratory Variation in the Immunohistochemical Determination of Estrogen Receptor Status Using a Breast Cancer Tissue Microarray. <i>American Journal of Clinical Pathology</i> , 2002, 117, 723-728.	0.4	150
59	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 343-350.	0.9	146
60	Acute Cigarette Smoke-Induced Connective Tissue Breakdown Is Mediated by Neutrophils and Prevented by Î± 1-Antitrypsin. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000, 22, 244-252.	1.4	145
61	Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry. <i>Modern Pathology</i> , 2002, 15, 1374-1380.	2.9	143
62	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. <i>American Journal of Surgical Pathology</i> , 2010, 34, 984-993.	2.1	143
63	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans. <i>American Journal of Pathology</i> , 2003, 163, 2383-2395.	1.9	142
64	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , 2015, 6, 37663-37677.	0.8	142
65	Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2. <i>Cancer Research</i> , 2006, 66, 4872-4879.	0.4	139
66	Endometrial Carcinomas with <i>POLE</i> Exonuclease Domain Mutations Have a Favorable Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 2865-2873.	3.2	139
67	Small-Cell Carcinoma of the Endometrium. <i>American Journal of Surgical Pathology</i> , 1994, 18, 364-375.	2.1	138
68	Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression. <i>Cancer Research</i> , 2004, 64, 5068-5073.	0.4	136
69	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , 2010, 222, 191-198.	2.1	136
70	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2013, 121, 14-24.	1.2	134
71	Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology. <i>American Journal of Pathology</i> , 2003, 163, 1449-1456.	1.9	133
72	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. <i>Journal of Pathology</i> , 2015, 236, 201-209.	2.1	131

#	ARTICLE	IF	CITATIONS
73	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. <i>Gynecologic Oncology</i> , 2010, 116, 50-56.	0.6	129
74	Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the Ovary. <i>American Journal of Surgical Pathology</i> , 2011, 35, 36-44.	2.1	129
75	Synchronous and Metachronous Endocervical and Ovarian Neoplasms. <i>American Journal of Surgical Pathology</i> , 2005, 29, 281-294.	2.1	128
76	Frequency of Known Gene Rearrangements in Endometrial Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1364-1372.	2.1	128
77	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv428.	3.0	128
78	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009, 22, 469-475.	2.9	125
79	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. <i>Modern Pathology</i> , 2004, 17, 690-695.	2.9	123
80	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 302-314.	2.9	123
81	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 481-489.	1.5	116
82	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1421-1432.	2.1	115
83	A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1596-1606.	2.1	115
84	Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 200-205.	0.9	114
85	Subtype-specific mutation of <i>PPP2R1A</i> in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , 2011, 223, 567-573.	2.1	114
86	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017, 23, 4086-4094.	3.2	114
87	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. <i>Gynecologic Oncology</i> , 2008, 110, 408-417.	0.6	113
88	Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 129-137.	0.9	112
89	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	0.9	111
90	Uterine Adenomyomas Excluding Atypical Polypoid Adenomyomas and Adenomyomas of Endocervical Type: A Clinicopathologic Study of 30 Cases of an Underemphasized Lesion That May Cause Diagnostic Problems with Brief Consideration of Adenomyomas of Other Female Genital Tract Sites. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 195-205.	0.9	110

#	ARTICLE	IF	CITATIONS
91	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014, 27, 255-261.	2.9	110
92	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3935.	5.8	110
93	Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation. <i>Journal of Clinical Oncology</i> , 2012, 30, 1656-1662.	0.8	109
94	The Histomorphology of Lynch Syndrome-associated Ovarian Carcinomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1173-1181.	2.1	108
95	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. <i>Laboratory Investigation</i> , 2005, 85, 1392-1404.	1.7	107
96	Testing Women With Endometrial Cancer to Detect Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, 2247-2252.	0.8	107
97	Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment. <i>Annals of Surgical Oncology</i> , 2007, 14, 719-729.	0.7	106
98	Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy. <i>Obstetrics and Gynecology</i> , 2015, 125, 338-345.	1.2	106
99	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , 2014, 64, 1004-1013.	1.6	104
100	Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases. <i>American Journal of Surgical Pathology</i> , 2015, 39, 357-364.	2.1	104
101	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. <i>Modern Pathology</i> , 2020, 33, 1595-1605.	2.9	103
102	Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. <i>Cancer</i> , 2005, 103, 1770-1777.	2.0	102
103	Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems. <i>American Journal of Surgical Pathology</i> , 2005, 29, 295-304.	2.1	101
104	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548.	3.2	101
105	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. <i>Gynecologic Oncology</i> , 2005, 96, 684-694.	0.6	100
106	The fibromatosis signature defines a robust stromal response in breast carcinoma. <i>Laboratory Investigation</i> , 2008, 88, 591-601.	1.7	100
107	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011, 24, 512-521.	2.9	95
108	Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. <i>Histopathology</i> , 2017, 71, 238-246.	1.6	92

#	ARTICLE	IF	CITATIONS
109	Immunolocalization of Gonadotropin-Releasing Hormone (GnRH)-I, GnRH-II, and Type I GnRH Receptor during Follicular Development in the Human Ovary. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4562-4570.	1.8	91
110	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 417-426.	1.1	91
111	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 99-107.	0.9	90
112	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , 2013, 62, 59-70.	1.6	90
113	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , 2016, 29, 1586-1593.	2.9	87
114	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. <i>British Journal of Cancer</i> , 2018, 119, 480-486.	2.9	86
115	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. <i>Gynecologic Oncology</i> , 2005, 96, 48-55.	0.6	85
116	Mixed Ovarian Epithelial Carcinomas With Clear Cell and Serous Components are Variants of High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 955-964.	2.1	84
117	MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary. <i>PLoS ONE</i> , 2009, 4, e7314.	1.1	83
118	Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. <i>American Journal of Pathology</i> , 2009, 174, 2347-2356.	1.9	83
119	Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival. <i>Cancer Research</i> , 2004, 64, 286-291.	0.4	82
120	The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. <i>PLoS ONE</i> , 2009, 4, e7988.	1.1	82
121	Papillary Serous Carcinoma of the Uterine Cervix. <i>American Journal of Surgical Pathology</i> , 1998, 22, 113-120.	2.1	82
122	Advanced-Stage Serous Borderline Tumors of the Ovary: A Clinicopathological Study of 49 Cases. <i>International Journal of Gynecological Pathology</i> , 2003, 22, 29-36.	0.9	81
123	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017, 41, 245-252.	2.1	81
124	Endometrial Stromal Sarcomas With Sex Cord Differentiation Are Associated With PHF1 Rearrangement. <i>American Journal of Surgical Pathology</i> , 2013, 37, 514-521.	2.1	79
125	Detection of the EWS/WT1 Gene Fusion by Reverse Transcriptase-Polymerase Chain Reaction in the Diagnosis of Intra-abdominal Desmoplastic Small Round Cell Tumor. <i>American Journal of Surgical Pathology</i> , 1996, 20, 406-412.	2.1	79
126	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. <i>Gynecologic Oncology</i> , 2006, 100, 264-270.	0.6	78

#	ARTICLE	IF	CITATIONS
127	Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. <i>Modern Pathology</i> , 2007, 20, 84-89.	2.9	78
128	A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. <i>Modern Pathology</i> , 2009, 22, 1519-1531.	2.9	78
129	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. <i>Cell Cycle</i> , 2013, 12, 1433-1449.	1.3	78
130	Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. <i>Gynecologic Oncology</i> , 2020, 158, 3-11.	0.6	78
131	The role of the fallopian tube in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 296-306.	0.3	77
132	Patterns of p53 immunoreactivity in endometrial carcinomas: "all or nothing" staining is of importance. <i>Histopathology</i> , 2011, 59, 786-788.	1.6	76
133	Rare cancers: a sea of opportunity. <i>Lancet Oncology</i> , The, 2016, 17, e52-e61.	5.1	76
134	Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2021, 45, 498-506.	2.1	76
135	Targeted transcriptional repression of Gfi1 by GFI1 and GFI1B in lymphoid cells. <i>Nucleic Acids Research</i> , 2004, 32, 2508-2519.	6.5	74
136	Canadian Association of Pathologists "Association canadienne des pathologistes National Standards Committee/Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2010, 133, 354-365.	0.4	74
137	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. <i>Modern Pathology</i> , 2013, 26, 860-867.	2.9	74
138	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019, 154, 441-448.	0.6	74
139	Vulval squamous cell carcinoma and its precursors. <i>Histopathology</i> , 2020, 76, 128-138.	1.6	73
140	Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 487-495.	0.6	72
141	Growth Factor Independence-1 Is Expressed in Primary Human Neuroendocrine Lung Carcinomas and Mediates the Differentiation of Murine Pulmonary Neuroendocrine Cells. <i>Cancer Research</i> , 2004, 64, 6874-6882.	0.4	71
142	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012, 118, 681-688.	2.0	71
143	Expanding the Morphologic Spectrum of Differentiated VIN (dVIN) Through Detailed Mapping of Cases With p53 Loss. <i>American Journal of Surgical Pathology</i> , 2015, 39, 52-60.	2.1	71
144	High-grade serous carcinoma of tubo-ovarian origin: recent developments. <i>Histopathology</i> , 2017, 71, 339-356.	1.6	71

#	ARTICLE	IF	CITATIONS
145	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE, 2011, 6, e21121.	1.1	71
146	Early stage uterine papillary serous carcinoma of the endometrium. Cancer, 2001, 91, 752-757.	2.0	70
147	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	1.1	70
148	Comparison of molecular abnormalities in vulvar and vaginal melanomas. Modern Pathology, 2014, 27, 1386-1393.	2.9	70
149	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. American Journal of Surgical Pathology, 2015, 39, 1548-1557.	2.1	70
150	p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. International Journal of Gynecological Pathology, 2016, 35, 385-393.	0.9	70
151	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. Journal of Pathology: Clinical Research, 2017, 3, 279-293.	1.3	70
152	Uterine leiomyosarcomas: Tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecologic Oncology, 2011, 121, 328-333.	0.6	69
153	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology, 2014, 65, 149-154.	1.6	69
154	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. Journal of Pathology, 2017, 243, 26-36.	2.1	69
155	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of β -HNF1 β and oestrogen receptor. Histopathology, 2014, 64, 585-596.	1.6	68
156	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
157	The origin of ovarian carcinomas: A developmental view. Gynecologic Oncology, 2008, 110, 452-454.	0.6	67
158	Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. Clinical Cancer Research, 2011, 17, 783-791.	3.2	67
159	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	1.1	67
160	Mineral Dusts Directly Induce Epithelial and Interstitial Fibrogenic Mediators and Matrix Components in the Airway Wall. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1907-1913.	2.5	65
161	Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. International Journal of Gynecological Pathology, 2012, 31, 499-506.	0.9	65
162	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology, 2016, 68, 916-924.	1.6	65

#	ARTICLE	IF	CITATIONS
163	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <i>Oncogene</i> , 2005, 24, 7281-7289.	2.6	63
164	Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2005, 24, 147-152.	0.9	62
165	MDM2 protein expression is a negative prognostic marker in breast carcinoma. <i>Modern Pathology</i> , 2006, 19, 69-74.	2.9	62
166	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 628-638.	2.1	62
167	Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. <i>Journal of Pathology</i> , 2021, 253, 355-365.	2.1	62
168	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	2.0	62
169	Interobserver Variability in the Interpretation of Tumor Cell Necrosis in Uterine Leiomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 650-658.	2.1	60
170	Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. <i>Gynecologic Oncology</i> , 2016, 141, 195-198.	0.6	60
171	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , 2008, 110, 256-264.	0.6	59
172	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. <i>Neoplasia</i> , 2015, 17, 650-660.	2.3	59
173	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , 2007, 20, 1156-1165.	2.9	58
174	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. <i>Cancer Research</i> , 2009, 69, 9160-9162.	0.4	58
175	Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF- β 2 Pathway Signaling Indicates Response to Primary Chemotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 2852-2860.	3.2	58
176	Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 161-170.	2.1	58
177	Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. <i>British Journal of Cancer</i> , 2016, 115, 993-999.	2.9	55
178	Early Recurrence of Ovarian Serous Borderline Tumor as High-grade Carcinoma: A Report of Two Cases. <i>International Journal of Gynecological Pathology</i> , 2004, 23, 265-272.	0.9	54
179	Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. <i>American Journal of Surgery</i> , 2006, 191, 581-587.	0.9	54
180	Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours. <i>Histopathology</i> , 2016, 69, 560-569.	1.6	54

#	ARTICLE	IF	CITATIONS
181	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018, 151, 53-60.	0.6	54
182	HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. <i>Annals of Surgery</i> , 2010, 251, 1107-1116.	2.1	53
183	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. <i>Journal of Pathology</i> , 2020, 252, 178-188.	2.1	53
184	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007, 5, 33.	2.3	52
185	Identifying Lynch Syndrome in Patients With Ovarian Carcinoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 378-386.	2.4	52
186	Loss of the Notch effector RBPJ promotes tumorigenesis. <i>Journal of Experimental Medicine</i> , 2015, 212, 37-52.	4.2	52
187	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , 2016, 69, 727-738.	1.6	52
188	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw134.	3.0	52
189	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , 2016, 40, 166-180.	2.1	51
190	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 239-252.	1.7	50
191	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	0.6	50
192	HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 507-516.	0.9	50
193	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , 2018, 31, 1107-1115.	2.9	49
194	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 552-560.	0.6	49
195	The secondary Müllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. <i>Pathology</i> , 2015, 47, 423-431.	0.3	48
196	Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma. <i>Journal of Oncology</i> , 2010, 2010, 1-7.	0.6	47
197	Aggressive Behavior of Stage I Ovarian Mucinous Tumors Lacking Extensive Infiltrative Invasion: A Report of Four Cases and Review of the Literature. <i>International Journal of Gynecological Pathology</i> , 2005, 24, 205-217.	0.9	46
198	Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). <i>Histopathology</i> , 2022, 80, 762-778.	1.6	46

#	ARTICLE	IF	CITATIONS
199	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
200	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 353-362.	0.9	45
201	Aluminum-Induced Pulmonary Fibrosis: Do Fibers Play a Role?. <i>The American Review of Respiratory Disease</i> , 1987, 136, 176-179.	2.9	44
202	Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. <i>Differentiation</i> , 2006, 74, 1-10.	1.0	44
203	Endometrial Carcinomas With Clear Cells. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 323-333.	0.9	44
204	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 230-237.	0.9	44
205	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
206	Performance of the patternâ€based interpretation of p53 immunohistochemistry as a surrogate for <i>TP53</i> mutations in vulvar squamous cell carcinoma. <i>Histopathology</i> , 2020, 77, 92-99.	1.6	42
207	Ovarian Cellular Fibromas Lack FOXL2 Mutations. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1450-1455.	2.1	41
208	Markers of Proliferative Activity Are Predictors of Patient Outcome for Low-Grade Endometrioid Adenocarcinoma But Not Papillary Serous Carcinoma of Endometrium. <i>Modern Pathology</i> , 2002, 15, 365-371.	2.9	40
209	Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. <i>Cancer Research</i> , 2009, 69, 4843-4850.	0.4	40
210	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 555-561.	0.9	40
211	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. <i>Modern Pathology</i> , 2021, 34, 508-518.	2.9	40
212	Assessment of a new system for primary site assignment in highâ€grade serous carcinoma of the fallopian tube, ovary, and peritoneum. <i>Histopathology</i> , 2015, 67, 331-337.	1.6	39
213	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 885-896.	1.4	39
214	Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. , 1999, 25, 40-48.		38
215	Immunohistochemical Survey of Mismatch Repair Protein Expression in Uterine Sarcomas and Carcinosarcomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 483-491.	0.9	38
216	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409.	1.1	37

#	ARTICLE	IF	CITATIONS
217	p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 907-913.	1.2	37
218	Better Therapeutic Trials in Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju029-dju029.	3.0	36
219	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2016, 114, 417-426.	2.9	35
220	Biomarker Expression in Pelvic High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2011, 30, 366-371.	0.9	34
221	Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 529-535.	0.9	34
222	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	0.6	34
223	Trichoblastic Fibroma A Clinicopathologic Study of Three Cases. <i>American Journal of Dermatopathology</i> , 1989, 11, 397-402.	0.3	33
224	CSF1 Expression in Nongynecological Leiomyosarcoma Is Associated with Increased Tumor Angiogenesis. <i>American Journal of Pathology</i> , 2011, 179, 2100-2107.	1.9	33
225	Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1334-1358.	1.8	33
226	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 172-179.	0.9	33
227	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tuboovarian high-grade serous carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 252-262.	1.3	33
228	Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. <i>Pathology</i> , 2008, 40, 611-616.	0.3	32
229	Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 289-293.	0.9	32
230	HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1495-1502.	1.2	31
231	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 230-239.	0.9	31
232	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , 2011, 24, 277-287.	2.9	30
233	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors) Tj ETQq1 1 0.784314 rgBT /Overl 2016, 40, 1155-1164.	2.1	30
234	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 483-490.	1.1	30

#	ARTICLE	IF	CITATIONS
235	Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors. <i>Gynecologic Oncology</i> , 2015, 138, 141-146.	0.6	29
236	FOXL2 C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 126-136.	1.2	29
237	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
238	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 100-106.	1.2	29
239	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 209-221.	0.9	28
240	DICER1 hot-spot mutations in ovarian gynandroblastoma. <i>Histopathology</i> , 2018, 73, 306-313.	1.6	28
241	Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 558-563.	0.6	28
242	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 33705-33719.	0.8	28
243	New Insights Into the Pathogenesis of Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2012, 120, 935-940.	1.2	27
244	Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. <i>Histopathology</i> , 2014, 64, 840-846.	1.6	27
245	Assessment of CK17 as a Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 273-280.	0.9	27
246	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 243-252.	1.3	27
247	A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , 2017, 71, 736-742.	1.6	27
248	FOXL2 Mutation is Absent in Uterine Tumors Resembling Ovarian Sex Cord Tumors. <i>American Journal of Surgical Pathology</i> , 2015, 39, 618-623.	2.1	26
249	The cell surface mucin podocalyxin regulates collective breast tumor budding. <i>Breast Cancer Research</i> , 2016, 18, 11.	2.2	26
250	Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. <i>Gynecologic Oncology</i> , 2004, 93, 315-319.	0.6	25
251	HOXA7 in Epithelial Ovarian Cancer: Interrelationships Between Differentiation and Clinical Features. <i>Reproductive Sciences</i> , 2007, 14, 605-614.	1.1	25
252	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , 2012, 60, 547-553.	1.6	25

#	ARTICLE	IF	CITATIONS
253	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014, 33, 560-567.	0.9	25
254	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	0.6	25
255	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. <i>Histopathology</i> , 2017, 71, 446-452.	1.6	25
256	Does MMR status in endometrial cancer influence response to adjuvant therapy?. <i>Gynecologic Oncology</i> , 2018, 151, 76-81.	0.6	25
257	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 537-545.	0.9	25
258	Spontaneous Pulmonary Hemorrhage After Thrombolytic Therapy for Acute Myocardial Infarction. <i>Chest</i> , 1994, 106, 1622-1624.	0.4	24
259	Synchronous tumours of the female reproductive tract. <i>Pathology</i> , 2018, 50, 214-221.	0.3	24
260	Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. <i>Histopathology</i> , 2021, 78, 424-433.	1.6	24
261	Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?. <i>Clinical Cancer Research</i> , 2011, 17, 7273-7282.	3.2	23
262	HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva. <i>Modern Pathology</i> , 2022, 35, 1317-1326.	2.9	23
263	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. <i>Surgical Pathology Clinics</i> , 2016, 9, 189-199.	0.7	22
264	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	1.4	22
265	Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. <i>Histopathology</i> , 2014, 64, 626-632.	1.6	21
266	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. <i>Histopathology</i> , 2017, 70, 56-69.	1.6	21
267	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	3.2	21
268	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	2.9	21
269	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021, 160, 568-578.	0.6	21
270	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1132-1138.	2.1	20

#	ARTICLE	IF	CITATIONS
271	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , 2016, 45, 119-125.	0.8	20
272	Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 189-195.	0.9	20
273	Napsin-A and AMACR are Superior to HNF-1 β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 593-601.	0.6	20
274	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. <i>Gynecologic Oncology</i> , 2022, 165, 376-384.	0.6	20
275	Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 589-598.	1.4	19
276	Opportunistic salpingectomy for women at low risk for development of ovarian carcinoma: The time has come. <i>Gynecologic Oncology</i> , 2013, 129, 443-444.	0.6	19
277	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	1.8	19
278	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. <i>BMC Cancer</i> , 2018, 18, 254.	1.1	19
279	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. <i>Histopathology</i> , 2019, 75, 813-824.	1.6	19
280	The utility of color normalization for AI-based diagnosis of hematoxylin and eosin-stained pathology images. <i>Journal of Pathology</i> , 2022, 256, 15-24.	2.1	19
281	KrÄppel-Like Factor 5 Is Not Required for K-RasG12D Lung Tumorigenesis, but Represses ABCG2 Expression and Is Associated with Better Disease-Specific Survival. <i>American Journal of Pathology</i> , 2010, 177, 1503-1513.	1.9	18
282	Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. <i>American Journal of Surgery</i> , 2012, 203, 654-659.	0.9	18
283	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 157, 12-20.	0.6	18
284	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. <i>Gynecologic Oncology</i> , 2022, 165, 201-214.	0.6	18
285	Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7958-7964.	3.2	17
286	Vulvar Acanthosis With Altered Differentiation (VAAD). <i>International Journal of Gynecological Pathology</i> , 2015, 34, 385-389.	0.9	17
287	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. <i>Modern Pathology</i> , 2020, 33, 1649-1659.	2.9	17
288	Mitotic Arrest of Endometrial Epithelium After Paclitaxel Therapy for Breast Cancer. <i>International Journal of Gynecological Pathology</i> , 2000, 19, 395-397.	0.9	16

#	ARTICLE	IF	CITATIONS
289	Papillary serous carcinomaâ€”A less radio-sensitive subtype of endometrial cancer. <i>Gynecologic Oncology</i> , 2005, 98, 299-303.	0.6	16
290	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2020, 44, 495-502.	2.1	16
291	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 517-527.	0.9	15
292	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018, 47, 450-459.	0.9	15
293	Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 353-356.	1.2	15
294	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€”associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	2.1	15
295	It Sounded Like a Good Idea at the Time. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 1127-1130.	0.3	14
296	Utility of a CEA, CD15, Calretinin, and CK5/6 Panel for Distinguishing Between Mesotheliomas and Pulmonary Adenocarcinomas in Clinical Practice. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1503-1508.	2.1	14
297	Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3967-3973.	0.8	14
298	Use of Immunohistochemical Markers (HNF-1 β , Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 344-353.	0.9	14
299	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin. , 2020, 8, e001128.		14
300	Effects of Cigarette Smoke On Tissue Uptake and Retention of Iron Oxide in the Guinea Pig. <i>The American Review of Respiratory Disease</i> , 1988, 137, 1382-1384.	2.9	13
301	Luteinized Thecomas (Thecomatosis) Associated With Sclerosing Peritonitis Exhibit Positive Staining With Sex Cord Markers Steroidogenic Factor-1 (SF-1) and FOXL2. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1458-1459.	2.1	13
302	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. <i>Histopathology</i> , 2017, 70, 185-194.	1.6	13
303	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 324-330.	0.9	13
304	Canadian Association of Pathologistsâ€”Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2014, 142, 629-633.	0.4	12
305	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , 2018, 31, 652-659.	2.9	12
306	Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma. <i>Histopathology</i> , 2019, 75, 442-445.	1.6	12

#	ARTICLE	IF	CITATIONS
307	Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 783-788.	1.2	12
308	Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1038-1046.	2.1	12
309	Artefactual punctate <sc>MLH</sc>1 staining can lead to erroneous reporting of isolated <sc>PMS</sc>2 loss. <i>Histopathology</i> , 2018, 73, 703-705.	1.6	11
310	Synchronous carcinomas of endometrium and ovary: A pragmatic approach. <i>Gynecologic Oncology Reports</i> , 2019, 27, 72-73.	0.3	11
311	Early stage uterine papillary serous carcinoma of the endometrium. <i>Cancer</i> , 2001, 91, 752-757.	2.0	11
312	Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. <i>Expert Review of Obstetrics and Gynecology</i> , 2013, 8, 67-82.	0.4	10
313	Patterns of spread of clear cell ovarian cancer: Case report and case series. <i>Gynecologic Oncology Case Reports</i> , 2013, 6, 25-27.	0.9	10
314	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 119-127.	0.9	10
315	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 12-19.	0.9	10
316	Performance of a HER2 testing algorithm specific for p53â€ abnormal endometrial cancer. <i>Histopathology</i> , 2021, 79, 533-543.	1.6	10
317	Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium. <i>Fertility and Sterility</i> , 2002, 78, 195-196.	0.5	9
318	Loss of Sprouty2 in human highâ€ grade serous ovarian carcinomas promotes EGFâ€ induced Eâ€ cadherin downâ€ regulation and cell invasion. <i>FEBS Letters</i> , 2015, 589, 302-309.	1.3	9
319	Precision medicine in endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 451-453.	0.6	9
320	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. <i>Human Pathology</i> , 2019, 92, 39-47.	1.1	9
321	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , 2020, 157, 36-45.	0.6	9
322	Development of an Evidence-Based Approach to External Quality Assurance for Breast Cancer Hormone Receptor Immunohistochemistry: Comparison of Reference Values. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 874-881.	1.2	9
323	Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a â€ low-grade serous tubal intra-epithelial carcinomaâ€ (STIC) on risk reducing surgery. <i>Gynecologic Oncology Reports</i> , 2015, 12, 72-74.	0.3	8
324	Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1624-1630.	1.2	8

#	ARTICLE	IF	CITATIONS
325	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. <i>Human Pathology</i> , 2021, 108, 1-11.	1.1	8
326	Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. <i>PLoS ONE</i> , 2014, 9, e102370.	1.1	8
327	Biological Effects of Biliary Shock Wave Lithotripsy in Swine. <i>Investigative Radiology</i> , 1989, 24, 366-370.	3.5	7
328	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 487-494.	0.9	7
329	Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 391-399.	0.9	7
330	A NOVEL LYMPHOCYTE ACTIVATION ANTIGEN PRESENT ON ALLOSPECIFIC PRIMED LYMPHOCYTES AND DEFINED BY THE MONOCLONAL ANTIBODY VG01. <i>Transplantation</i> , 1988, 45, 978-984.	0.5	6
331	Amyloidosis of the Uterine Cervix Presenting as Postmenopausal Bleeding. <i>Obstetrics and Gynecology</i> , 2001, 98, 966-968.	1.2	6
332	Spontaneous Regression of Stage IV Clear Cell Carcinoma of the Endometrium in a Patient with Essential Thrombocytosis. <i>Gynecologic Oncology</i> , 2001, 82, 395-399.	0.6	6
333	SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. <i>Gynecologic Oncology</i> , 2008, 111, 125-131.	0.6	6
334	Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. <i>Pathology</i> , 2010, 42, 637-642.	0.3	6
335	Letter to the editor regarding Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression. <i>Modern Pathology</i> , 2011, 24, 1281-1282.	2.9	6
336	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , 2017, 71, 1014-1017.	1.6	6
337	Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. <i>Histopathology</i> , 2020, 76, 521-530.	1.6	6
338	Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 19-25.	0.9	6
339	Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 420-427.	0.9	6
340	Primary mucinous ovarian neoplasms rarely show germ cell histogenesis. <i>Histopathology</i> , 2021, 78, 640-642.	1.6	6
341	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. <i>Mod Pathol</i> 2020; 33:871-879. <i>Modern Pathology</i> , 2021, 34, 1031-1032.	2.9	6
342	Synchronous and Metachronous Endocervical and Ovarian Neoplasms: A Different Interpretation of HPV Data. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1687-1689.	2.1	5

#	ARTICLE	IF	CITATIONS
343	High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum. <i>Surgical Pathology Clinics</i> , 2011, 4, 375-396.	0.7	5
344	Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 686-696.	0.6	5
345	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. <i>Cancer Medicine</i> , 2020, 9, 6507-6514.	1.3	5
346	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , 2020, 101, 40-52.	1.1	4
347	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. <i>Modern Pathology</i> , 2008, 21, 1413-1420.	2.9	3
348	The Laboratory Score/Reference Method Score Ratio (LSRSR) Is a Novel Tool for Monitoring Laboratory Performance in Immunohistochemistry Proficiency Testing of Hormone Receptors in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2011, 136, 67-73.	0.4	3
349	The most important discoveries of the past 50 years in gynaecological pathology. <i>Histopathology</i> , 2020, 76, 6-10.	1.6	3
350	Online Training and Self-assessment in the Histopathologic Classification of Endocervical Adenocarcinoma and Diagnosis of Pattern of Invasion: Evaluation of Participant Performance. <i>International Journal of Gynecological Pathology</i> , 2021, 40, S14-S23.	0.9	3
351	The impact of whole genome and transcriptome analysis (<scp>WGTA</scp>) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 395-407.	1.3	3
352	Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract. <i>Surgical Pathology Clinics</i> , 2009, 2, 823-834.	0.7	2
353	Case report: an identical twin with Sertoli-Leydig cell tumor. <i>Gynecological Endocrinology</i> , 2018, 34, 563-566.	0.7	2
354	The changing landscape of gynaecological pathology: WHO 2020 and beyond. <i>Histopathology</i> , 2020, 76, 2-5.	1.6	2
355	Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2021, 18, 3464-3474.	2.3	2
356	Surgical staging of early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 122, 460-461.	0.6	1
357	Academic and Nonacademic Laboratories Perform Equally on CIQC Immunohistochemistry Proficiency Testing. <i>American Journal of Clinical Pathology</i> , 2013, 140, 55-60.	0.4	1
358	Mutations in oncogenes: Context matters. <i>Gynecologic Oncology</i> , 2014, 134, 1-2.	0.6	1
359	Ovarian carcinoma histotype in Lynch syndrome. <i>Gynecologic Oncology Reports</i> , 2017, 20, 140-141.	0.3	1
360	Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 514-521.	0.9	1

#	ARTICLE	IF	CITATIONS
361	Ovarian borderline tumours and carcinomas: an update. <i>Diagnostic Histopathology</i> , 2021, 27, 500-505.	0.2	1
362	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020, 15, e0240412.	1.1	1
363	Identification of a novel subtype of endometrial cancer with unfavorable outcome using artificial intelligence-based histopathology image analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5594-5594.	0.8	1
364	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 442-444.	0.2	0
365	Minutes of the 2018 Annual Business Meeting of International Society of Gynecological Pathologists (ISGyP). <i>International Journal of Gynecological Pathology</i> , 2019, 38, 108-109.	0.9	0
366	Prognostic Factors in Paget's Disease of the Vulva: A Study of 21 Cases. <i>Obstetrical and Gynecological Survey</i> , 2000, 55, 218-219.	0.2	0
367	Immunoreactive Acellular Keratin in Sentinel Lymph Nodes From a Patient With Endometrioid Carcinoma of the Endometrium With Squamous Differentiation: A Case Report of a Potential Diagnostic Pitfall. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 355-358.	0.9	0
368	Title is missing!. , 2020, 15, e0240412.		0
369	Title is missing!. , 2020, 15, e0240412.		0
370	Title is missing!. , 2020, 15, e0240412.		0
371	Title is missing!. , 2020, 15, e0240412.		0